Targetable CD4+ T-cell TGFβ Signaling Suppresses Antitumor Immunity

Article navigation

Research Watch| December 01 2020

Targetable CD4⁺ T-cell TGFβ Signaling Suppresses Antitumor Immunity

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2020

American Association for Cancer Research.

Cancer Discov (2020) 10 (12): 1785.

Ablating TGFβ signaling by CD4⁺ T cells remodeled tumor vasculature to cause cancer-cell death.

2020

American Association for Cancer Research.

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.